Neuromed Pharmaceuticals' rationale for paying $30 million up front plus milestones and royalties to Johnson & Johnson subsidiary ALZA Corp. in exchange for U.S. rights to OROS Hydromorphone might not be intuitively obvious. (BioWorld Today) Read More
